G7 Synergon Profile
Key Indicators
- Authorised Capital ₹ 12.50 Cr
as on 13-01-2025
- Paid Up Capital ₹ 12.01 Cr
as on 13-01-2025
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
About G7 Synergon
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 12.50 Cr and a paid-up capital of Rs 12.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
Durairaj Sathishkumar and Rajagopal Nandhinidevi serve as directors at the Company.
- CIN/LLPIN
U72200KA2008PTC047522
- Company No.
047522
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does G7 Synergon Private Limited offer?
G7 Synergon Private Limited offers a wide range of products and services, including Data Entry & Data Processing Service, Data Management, Pharma & Bioanalytical Services, Pharmaceutical Services, IT, Networking & Automation Solution, IT Solutions.
Who are the key members and board of directors at G7 Synergon?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Durairaj Sathishkumar  | Director | 30-Dec-2013 | Current |
| Rajagopal Nandhinidevi | Director | 26-Sep-2015 | Current |
Financial Performance of G7 Synergon.
G7 Synergon Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of G7 Synergon?
In 2021, G7 Synergon had a promoter holding of 99.92% and a public holding of 0.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Therapolis Labs LlpActive 7 years 4 monthsDurairaj Sathishkumar and Rajagopal Nandhinidevi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at G7 Synergon?
G7 Synergon has a workforce of 4 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of G7 Synergon, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped G7 Synergon's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
